Targeting Lymphoma-associated Macrophage Expansion via CSF1R/JAK Inhibition is a Therapeutic Vulnerability in Peripheral T-cell Lymphomas

• Published in: Cancer research communications 2022-12, Vol.2 (12), p.1727-1737
• Main Authors: Gao, Xin, Kady, Nermin, Wang, Chenguang, Abdelrahman, Suhaib, Gann, Peter, Sverdlov, Maria, Wolfe, Ashley, Brown, Noah, Reneau, John, Robida, Aaron M, Murga-Zamalloa, Carlos, Wilcox, Ryan A
• Format: Article
• Language: English
• Subjects: Animals; Cytokines - pharmacology; Hematological Cancers; Humans; Immunology; Janus Kinase Inhibitors - pharmacology; Lymphoma, T-Cell - drug therapy; Lymphoma, T-Cell, Peripheral - drug therapy; Macrophages; Mice; Progression, Invasion & Metastasis; Small Molecule Agents; Tumor Microenvironment
• ISSN: 2767-9764; 2767-9764
• DOI: 10.1158/2767-9764.CRC-22-0336

The reciprocal relationship between malignant T cells and lymphoma-associated macrophages (LAM) within the tumor microenvironment (TME) is unique, as LAMs are well poised to provide ligands for antigen, costimulatory, and cytokine receptors that promote T-cell lymphoma growth. Conversely, malignant T cells promote the functional polarization and homeostatic survival of LAM. Therefore, we sought to determine the extent to which LAMs are a therapeutic vulnerability in these lymphomas, and to identify effective therapeutic strategies for their depletion. We utilized complementary genetically engineered mouse models and primary peripheral T-cell lymphoma (PTCL) specimens to quantify LAM expansion and proliferation. A high-throughput screen was performed to identify targeted agents that effectively deplete LAM within the context of PTCL. We observed that LAMs are dominant constituents of the TME in PTCL. Furthermore, their dominance was explained, at least in part, by their proliferation and expansion in response to PTCL-derived cytokines. Importantly, LAMs are a true dependency in these lymphomas, as their depletion significantly impaired PTCL progression. These findings were extrapolated to a large cohort of human PTCL specimens where LAM proliferation was observed. A high-throughput screen demonstrated that PTCL-derived cytokines led to relative resistance to CSF1R selective inhibitors, and culminated in the identification of dual CSF1R/JAK inhibition as a novel therapeutic strategy to deplete LAM in these aggressive lymphomas. Malignant T cells promote the expansion and proliferation of LAM, which are a dependency in these lymphomas, and are effectively depleted with a dual CSF1R/JAK inhibitor. LAMs are a therapeutic vulnerability, as their depletion impairs T-cell lymphoma disease progression. Pacritinib, a dual CSF1R/JAK inhibitor, effectively impaired LAM viability and expansion, prolonged survival in preclinical T-cell lymphoma models, and is currently being investigated as a novel therapeutic approach in these lymphomas.